| TOTAL: $43.8M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
|
| ||||
Alizyme plc |
Takeda Pharmaceutical Co. Ltd. (Japan) |
$2 |
Milestone payment |
Triggered by Takeda beginning a Phase II trial in Japan of cetilistat for treating obesity and related diseases (1/20) |
Array |
AstraZeneca plc (UK) |
$1 |
Milestone payment |
Triggered by selection of an additional clinical candidate in their small-molecule cancer program that began in December 2003 (1/24) |
Avanir |
AstraZeneca plc (UK) |
$5 |
Milestone payment |
Triggered by initiation of Phase I trials of AZD2479, a reverse cholesterol transport enhancer being developed under their July 2005 collaboration (1/3) |
Codexis Inc.* |
Bristol-Myers Squibb Co. |
ND |
Milestone payment |
Triggered by achievement of the research milestone in their deal focused on improving biocatalyst productivity of a BMS product candidate (1/31) |
Codexis Inc.* |
Arch Pharmalabs Ltd. (India) |
ND |
Milestone payment |
Arch integrated Codexis' biological catalysts and biocatalytic system into production of an intermediate used in the manufacture of a active pharmaceutical ingredient (1/5) |
Cytori |
Olympus-Cytori Joint Venture (JV with Olympus Corp.; Japan) |
$11 |
Milestone payment |
Triggered by gaining the CE Mark, or approval in Europe, for the Celution System ,a device that can process adult stem cells from adipose (1/24) |
4SC AG |
Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) |
ND |
Milestone payment |
Triggered by 4SC's identification of active agents against targets provided by SKK, under their January 2005 collaboration (1/17) |
Human Genome |
GlaxoSmithKline plc (UK) |
$5 |
Milestone payment |
Triggered by GSK's filing of an investigational new drug application to begin Phase I trials of GSK716155 (formerly Albugon) for treating diabetes (1/10) |
ImmunoGen |
Genentech Inc. (NYSE:DNA) |
$2 |
Milestone payment |
Triggered by the effectiveness of the IND application submitted by Genentech for the cancer product trastuzumab-DM1 (1/31) |
Medarex Inc.(MEDX) |
ImClone Systems Inc. (IMCL) |
ND |
Milestone payment |
Triggered by acceptance of an IND application for a fully human IgG1 antibody, developed using Medarex technology, for treating cancer (1/30) |
Medarex Inc. |
NovImmune SA* (Switzerland) |
ND |
Milestone payment |
Triggered by NovImmune's filing of an IND to begin trials of NI-0401, a fully human antibody developed using Medarex technology, for treating autoimmune disease (1/19) |
MorphoSys |
F. Hofmmann- La Roche Ltd. (Switzerland) |
ND |
Milestone payment |
Triggered by Roche's start of a Phase I trial of a HuCAL-derived antibody to treat Alzheimer's disease (1/25) |
Pharmacopeia |
NV Organon (the Netherlands) |
ND |
Milestone payment |
Triggered by Pharmacopeia's delivery of two additional advanced lead compounds targetng metabolic and inflammatory diseases, under their 2002 collaboration (1/11) |
Rigel Pharmaceuticals Inc. (RIGL) |
Merck & Co. Inc. |
ND |
Milestone payment |
The payment was triggered by undisclosed progress in their work on ubiquitin ligases for cancer and potentially other diseases (1/30) |
Rigel |
Serono SA (Switzerland; NYSE:SRA) |
$5 |
Milestone payment |
Triggered by the progress on the IND application for R763, for which Phase I trials in cancer patients will begin later in 2006 (1/26) |
Tanox Inc. |
Genentech Inc. (NYSE:DNA) |
$12.8 |
Milestone payment |
The milestone was triggered by sales of Xolair exceeding $300M in 2005 (1/23) |
Trimeris Inc. |
Hoffmann-La Roche Inc. |
ND |
Milestone payment |
Triggered by selection of two next-generation fusion inhibitor peptides for co- development, TR-291144 and TR-290999 (1/17) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange. | ||||
